Zenith Health

Who are in the management team of Zenith Health?

As of March 2023, the management team of Zenith Health includes Mahendra C Raycha (Chairman & Managing Director), Neela Raycha, Atul Thakkar (Non-Executive Directors), Gaurang Vora, Tejas Thakkar, Rajeshkumar M Thakkar (Independent Directors), Akshit Raycha (Joint Managing Director), and Mihir Satishkumar Shah (Company Secretary & Compliance Officer). The team features a diverse mix of executive, non-executive, and independent directors.

As of March 2023, the management team of Zenith Health includes the following individuals:<BR><BR>1. Mahendra C Raycha - Chairman & Managing Director<BR>2. Neela Raycha - Non Executive Director<BR>3. Atul Thakkar - Non Executive Director<BR>4. Gaurang Vora - Independent Director<BR>5. Tejas Thakkar - Independent Director<BR>6. Rajeshkumar M Thakkar - Independent Director<BR>7. Akshit Raycha - Joint Managing Director<BR>8. Mihir Satishkumar Shah - Company Secretary & Compliance Officer<BR><BR>As of March 2023, the management team is composed of a mix of executive and non-executive directors, along with independent directors, reflecting a diverse governance structure within the company.

What does Zenith Health do?

Zenith Health Care Ltd manufactures pharmaceuticals, including tablets and injectables, and is a micro-cap company with a market cap of Rs 24 Cr. As of March 2025, it reported net sales of 3 Cr and a net profit of 0 Cr.

Overview: <BR>Zenith Health Care Ltd is engaged in the manufacturing of pharmaceuticals, including tablets, capsules, ointments, and liquid injectables, and operates within the Pharmaceuticals & Biotechnology industry as a micro-cap company.<BR><BR>History: <BR>Zenith Health Care Ltd was incorporated in 1994 and is ISO 9001:2008 & WHO-cGMP certified. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 24 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 24.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.35 <BR>Return on Equity: 0.92% <BR>Price to Book: 3.15 <BR><BR>Contact Details: <BR>Address: 504 Iscon Elegance S G Road, Nr Ananddham Jain Derasar Ahmedabad Gujarat : 380051 <BR>Tel: 91-79-66168889/66168890 <BR>Email: mahendrazenith@hotmail.com <BR>Website: http://www.zenithhealthcare.com

Has Zenith Health declared dividend?

No Dividend History Available

Who are the peers of the Zenith Health?

Zenith Health's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Ishita Drugs, Chemo Pharma Lab, Phaarmasia, Desh Rakshak, and Parmax Pharma. While Sun Pharma and others show excellent management and growth, Zenith Health has below-average ratings in these areas, with a 1-year return of 3.17%.

Peers: Zenith Health's peers include Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Ishita Drugs, Chemo Pharma Lab, Phaarmasia, Desh Rakshak, and Parmax Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Below Average management risk is found at Zenith Health, Ishita Drugs, Phaarmasia, Desh Rakshak, and Parmax Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Zenith Health, Divi's Lab., Torrent Pharma, Ishita Drugs, Phaarmasia, Desh Rakshak, and Parmax Pharma. Capital Structure is Excellent at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is seen at Torrent Pharma and Zenith Health, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Desh Rakshak at 422.50%, while the lowest is Phaarmasia at -24.74%. Zenith Health's own 1-year return is 3.17%, which is significantly lower than Desh Rakshak's but higher than Phaarmasia's. Additionally, peers such as Phaarmasia, Chemo Pharma Lab, and Parmax Pharma have negative six-month returns.

Is Zenith Health overvalued or undervalued?

As of July 22, 2024, Zenith Health is considered overvalued with a PE ratio of 24.18 and an EV to EBITDA of 21.55, especially when compared to peers like Sun Pharma and Cipla, and its stock has underperformed against the Sensex.

As of 22 July 2024, Zenith Health's valuation grade has moved from very expensive to risky, indicating a significant shift in its market perception. The company appears to be overvalued given its current metrics, with a PE ratio of 24.18, an EV to EBITDA of 21.55, and a PEG ratio of 0.00. These ratios suggest that while the company is generating some earnings, it is not doing so efficiently relative to its price.<BR><BR>In comparison to its peers, Zenith Health's valuation stands out unfavorably. For instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla, which is rated as attractive, has a PE ratio of 22.99 and an EV to EBITDA of 15.93. This peer comparison reinforces the notion that Zenith Health is overvalued in the current market context. Additionally, the company's stock has underperformed against the Sensex, particularly in the year-to-date and three-year periods, which further supports the case for its overvaluation.

What is the technical trend for Zenith Health?

As of May 20, 2025, Zenith Health's technical trend has shifted to bearish, supported by negative signals from the MACD, RSI, and moving averages, despite a mildly bullish KST.

As of 20 May 2025, the technical trend for Zenith Health has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from the weekly and monthly MACD, both showing bearish signals. The RSI on the monthly timeframe is also bearish, reinforcing the negative outlook. Daily moving averages confirm a bearish trend. While the KST on the weekly is mildly bullish, it does not outweigh the overall bearish sentiment from the other indicators. Bollinger Bands are mildly bearish on both weekly and monthly timeframes. Overall, the technical indicators suggest a bearish trend with significant weakness.

Who are the top shareholders of the Zenith Health?

The top shareholders of Zenith Health include Mahendra Chatrabhuj Raycha with 12.29%, and Sharpline Trading Co. Pvt. Ltd. with 3.29%. Individual investors hold a significant 64.12%, while there are no institutional or foreign institutional investors.

The top shareholders of Zenith Health include Mahendra Chatrabhuj Raycha, who holds the highest promoter stake at 12.29%. The highest public shareholder is Sharpline Trading Co. Pvt. Ltd., with a holding of 3.29%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 64.12% of the shares. There are no institutional investors or foreign institutional investors currently holding shares in the company.

How big is Zenith Health?

As of 24th July, Zenith Health Care Ltd has a market capitalization of 22.00 Cr, with recent net sales of 11.34 Cr and a net profit of 0.07 Cr over the latest four quarters. Shareholder's funds are valued at 7.34 Cr, and total assets amount to 9.63 Cr.

As of 24th July, <BR><BR>Market Cap: Zenith Health Care Ltd has a market capitalization of 22.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest four quarters is 11.34 Cr, while the sum of Net Profit for the same period is 0.07 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2024. Shareholder's Funds are valued at 7.34 Cr, and Total Assets amount to 9.63 Cr.

How has been the historical performance of Zenith Health?

Zenith Health's historical performance shows a decline in net sales from INR 22.36 crore in March 2022 to INR 11.33 crore in March 2025, with fluctuating profits and stable total assets and liabilities. Overall, the company has faced significant financial fluctuations, particularly in sales and profits.

Answer:<BR>The historical performance of Zenith Health shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Zenith Health's net sales have seen a decline from INR 22.36 crore in March 2022 to INR 11.33 crore in March 2025, with a notable drop in March 2024 to INR 14.47 crore and INR 13.13 crore in March 2023. The total operating income followed a similar pattern, decreasing from INR 22.36 crore in March 2022 to INR 11.33 crore in March 2025. The company's total expenditure, excluding depreciation, also decreased from INR 21.90 crore in March 2022 to INR 11.24 crore in March 2025. Operating profit (PBDIT) has fluctuated, peaking at INR 0.98 crore in March 2022 and dropping to INR 0.52 crore by March 2025. Profit before tax remained stable at INR 0.28 crore in both March 2024 and March 2025, while profit after tax decreased from INR 0.31 crore in March 2022 to INR 0.07 crore in March 2025. The company's total assets increased from INR 8.23 crore in March 2020 to INR 10.88 crore in March 2025, while total liabilities rose from INR 8.44 crore in March 2021 to INR 10.88 crore in March 2025. Cash flow from operating activities remained at zero in March 2025, with a cash outflow from investing activities of INR -1.00 crore. Overall, Zenith Health has experienced significant fluctuations in its financial performance, particularly in sales and profits, over the past several years.

When is the next results date for Zenith Health Care Ltd?

The next results date for Zenith Health Care Ltd is 29 May 2026.

The next results date for Zenith Health Care Ltd is scheduled for 29 May 2026.

Are Zenith Health Care Ltd latest results good or bad?

Zenith Health Care Ltd's latest results are concerning, showing a net loss of ₹0.34 crore for Q4 FY26 compared to a profit last year, with revenue down 23.62% year-on-year and a negative operating margin. Overall, the financial metrics indicate significant operational challenges, leading to a "STRONG SELL" recommendation for investors.

Zenith Health Care Ltd's latest results are concerning and indicate a significant decline in performance. For Q4 FY26, the company reported a net loss of ₹0.34 crore, a stark contrast to a profit of ₹0.11 crore in the same quarter last year. This reflects a deterioration in profitability.<BR><BR>Revenue also fell by 23.62% year-on-year to ₹2.62 crore, although there was a slight quarter-on-quarter improvement of 5.65%. The operating margin collapsed to -17.56%, down from a marginally positive 0.87% a year earlier, highlighting severe operational challenges and cost management issues.<BR><BR>The company's return on equity (ROE) stands at 5.98%, which is below industry standards, indicating poor capital efficiency. Additionally, the stock has underperformed significantly over the past year, declining 29.35% compared to the Sensex's 8.40% fall.<BR><BR>Overall, the financial metrics suggest that Zenith Health Care is facing critical operational challenges, and the outlook appears bleak, with multiple red flags indicating a "STRONG SELL" recommendation for investors.

Should I buy, sell or hold Zenith Health Care Ltd?

Which are the latest news on Zenith Health?

Why is Zenith Health Care Ltd falling/rising?

As of 03-Jun, Zenith Health Care Ltd's stock price is at 3.13, down 0.32%, and has underperformed its sector. The stock shows a consistent downward trend, with significant declines over various time frames, indicating negative investor sentiment.

As of 03-Jun, Zenith Health Care Ltd's stock price is falling, currently at 3.13, reflecting a change of -0.01 (-0.32%). The stock has underperformed its sector by 0.29% today and is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a downward trend in price performance. Over the past week, the stock has declined by 3.69%, while the benchmark Sensex decreased by only 2.01%. Additionally, the stock has shown a significant decline over longer periods, with a year-to-date drop of 6.57% and a staggering 30.91% decrease over the past year. Despite a rise in delivery volume by 39.62% against the 5-day average, the overall performance metrics suggest that investor sentiment remains negative, contributing to the stock's decline.